CDC COVID-19 Response Team.
MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-1645. doi: 10.15585/mmwr.mm7047e1.
Pregnant women are at increased risk for severe COVID-19-related illness, and COVID-19 is associated with an increased risk for adverse pregnancy outcomes and maternal and neonatal complications (1-3). To date, studies assessing whether COVID-19 during pregnancy is associated with increased risk for stillbirth have yielded mixed results (2-4). Since the B.1.617.2 (Delta) variant of SARS-CoV-2 (the virus that causes COVID-19) became the predominant circulating variant,* there have been anecdotal reports of increasing rates of stillbirths in women with COVID-19. CDC used the Premier Healthcare Database Special COVID-19 Release (PHD-SR), a large hospital-based administrative database, to assess whether a maternal COVID-19 diagnosis documented at delivery hospitalization was associated with stillbirth during March 2020-September 2021 as well as before and during the period of Delta variant predominance in the United States (March 2020-June 2021 and July-September 2021, respectively). Among 1,249,634 deliveries during March 2020-September 2021, stillbirths were rare (8,154; 0.65%): 273 (1.26%) occurred among 21,653 deliveries to women with COVID-19 documented at the delivery hospitalization, and 7,881 (0.64%) occurred among 1,227,981 deliveries without COVID-19. The adjusted risk for stillbirth was higher in deliveries with COVID-19 compared with deliveries without COVID-19 during March 2020-September 2021 (adjusted relative risk [aRR] = 1.90; 95% CI = 1.69-2.15), including during the pre-Delta (aRR = 1.47; 95% CI = 1.27-1.71) and Delta periods (aRR = 4.04; 95% CI = 3.28-4.97). COVID-19 documented at delivery was associated with increased risk for stillbirth, with a stronger association during the period of Delta variant predominance. Implementing evidence-based COVID-19 prevention strategies, including vaccination before or during pregnancy, is critical to reducing the impact of COVID-19 on stillbirths.
孕妇患严重与 COVID-19 相关疾病的风险增加,COVID-19 与不良妊娠结局以及母婴和新生儿并发症的风险增加有关 (1-3)。迄今为止,评估 COVID-19 感染是否与死胎风险增加有关的研究结果不一 (2-4)。自 SARS-CoV-2(导致 COVID-19 的病毒)的 B.1.617.2(Delta)变体成为主要传播变体以来*,有报道称 COVID-19 孕妇的死胎率增加。CDC 使用 Premier Healthcare Database Special COVID-19 Release (PHD-SR),一个大型基于医院的行政数据库,评估 2020 年 3 月至 2021 年 9 月期间分娩住院时记录的产妇 COVID-19 诊断是否与死胎有关,以及在美国 Delta 变体占主导地位期间(分别为 2020 年 3 月至 2021 年 6 月和 2021 年 7 月至 9 月)。在 2020 年 3 月至 2021 年 9 月期间的 1,249,634 例分娩中,死胎很少见(8,154;0.65%):273(1.26%)发生在 21,653 例 COVID-19 记录在分娩住院的产妇分娩中,7,881(0.64%)发生在 1,227,981 例无 COVID-19 的分娩中。与无 COVID-19 的分娩相比,COVID-19 产妇的死胎风险更高在 2020 年 3 月至 2021 年 9 月期间(调整后的相对风险 [aRR] = 1.90;95%CI = 1.69-2.15),包括在 Delta 之前(aRR = 1.47;95%CI = 1.27-1.71)和 Delta 期间(aRR = 4.04;95%CI = 3.28-4.97)。分娩时记录的 COVID-19 与死胎风险增加有关,在 Delta 变体占主导地位期间关联更强。实施基于证据的 COVID-19 预防策略,包括在怀孕前或怀孕期间接种疫苗,对于降低 COVID-19 对死胎的影响至关重要。